63 results about "Mitosis" patented technology

Breast cancer (BC) affects more than 2 million women and is the leading cause of cancer death in women worldwide. The aim of the present study was to determine whether the JNK / c-Jun pathway was involved in GR-mediated OCDO mitogenic activity and to explore the therapeutic targeting of this pathway in TNBC. The Inventors showed that the targeting of JNK1 in TNBC is essential to inhibit the mitogenic activity of OCDO. Accordingly, the present invention relates to a method of treating a subject suffering from breast cancer comprising administering to said subject a therapeutically effective amount of a JNK-1 inhibitor.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

The present invention relates to a pharmaceutical composition comprising mitogens and stress control pathway inhibitors for the treatment of cancer. The present invention more specifically relates to a pharmaceutical composition comprising FGF-2 and bortezomib or LB-100 and bortezomib for the treatment of cancer cells without compromising the survival of normal cells.

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

The invention relates to a neural tissue unit for use in implantation into the nervous system of a human or non-human mammal, wherein said neural tissue unit contains differentiated post-mitotic neuronal cells in an extracellular matrix, said unit being obtained from a cellular microcompartment comprising a hydrogel capsule surrounding the neural tissue unit, and said hydrogel capsule being at least partially removed before use of the neural tissue unit. The invention also relates to a process for preparing such a neural tissue unit.

The disclosure relates to methods of treating photoreceptor disease and / or inhibiting degeneration or death of photoreceptors. The methods comprise administering to a subject in need thereof a therapeutically effective amount of an inhibitor of mitogen-activated protein kinase 11 (MAPK11), an inhibitor of casein kinase 1 (CK1), or combinations thereof. This disclosure also relates to certain inhibitors of MAPK11 or CK1 and to pharmaceutical compositions that contain such inhibitors.

This invention relates to the field of biomedicine and discloses a composition for treating non-small cell lung cancer metastasis that targets replication stress vulnerability and its application. The composition includes a dual-responsive polymer prodrug, which consists of a block copolymer backbone, a matrix metalloproteinase cleavage peptide sequence coupled to the hydrophilic end, and an active molecular group coupled to the hydrophobic end based on an asymmetric grafting structure. The active molecular group comprises a replication stress inducer and an ATR kinase inhibitor. This invention maintains the amorphous phase of the micelle core through the asymmetric grafting structure, eliminating the permeation barrier caused by spontaneous crystallization of components. This amorphous core provides a proton permeation channel, ensuring the synchronous in-situ release of multiple target drugs, thereby blocking the DNA replication fork repair pathway and inducing mitotic catastrophe, maintaining the spatiotemporal overlap of multiple drug interventions in the pathological target area, and avoiding the risk of drug resistance.

The present invention relates to an antibody-drug conjugate binding to Nectin-2 and use thereof, in which a mouse monoclonal antibody (m12G1 clone) and a chimeric anti-Nectin-2 antibody (chimeric 12G1; c12G1), which are capable of specifically targeting Nectin-2, have been prepared. The c12G1 antibody specifically bound to the C2 domain of human Nectin-2 with high affinity, but did not bind to mouse Nectin-2. Subsequently, an antibody-drug conjugate comprising a c12G1 antibody conjugated to DM1 was prepared, and as a result of examining the cytotoxic effect thereof on cancer cells in vitro and in vivo, c12G1-DM1 induced cell cycle arrest in the mitotic stage of Nectin-2-positive ovarian cancer cells, but not in Nectin-2-negative cancer cells. c12G1-DM1 induced approximately 100-fold cytotoxicity at IC50 in the range of 0.1-7.4 nM in ovarian cancer cells as compared to normal IgG-DM1, and c12G1-DM1 exhibited approximately 91% tumor growth inhibition in a mouse xenograft model transplanted with OV-90 cells. These results suggest that c12G1-DM1 can be effectively used as a potential therapeutic agent for Nectin-2-positive ovarian cancer.

The invention relates to a neural tissue unit for use in implantation into the nervous system of a human or non-human mammal, wherein said neural tissue unit contains differentiated post-mitotic neuronal cells in an extracellular matrix, said unit being obtained from a cellular microcompartment comprising a hydrogel capsule surrounding the neural tissue unit, and said hydrogel capsule being at least partially removed before use of the neural tissue unit. The invention also relates to a process for preparing such a neural tissue unit.

A system for treating cancer is disclosed. According to an embodiment of the present invention, the system comprises: an electric field applying device for applying an electric field for tumor treatment; the delivery system is used for delivering a drug, and the drug comprises at least one of an immune checkpoint inhibitor and a chemical drug; the immune checkpoint inhibitor is selected from one of a duvaleriumab, a palbolizumab, an atelizumab, a Nasuliumab and a tereprenil monoclonal antibody; the chemical drug is selected from at least one of gemcitabine, cis-platinum, GEMOX and lenvatinib. According to the system, proliferation of the biliary tract cancer cells can be inhibited, migration of the biliary tract cancer cells can be inhibited, mitosis of the biliary tract cancer cells can be interfered, and immunogenic death of the biliary tract cancer cells can be promoted.

Cell culture media, cell culture compositions and methods for culturing cell populations (e.g., T-cell populations) are provided for expanding cell populations (e.g., T-cell populations). The media may comprise a basal growth medium, a serum or serum substitute, and one or more cytokines and / or cytokine inhibitors (e.g., IL-2, IL-4, TGF [beta], and / or anti-IFN [gamma] antibodies). The method may include contacting the population of T cells with the culture medium to expand the population of T cells. The population of T cells may comprise CD4 + and / or CD8 + primary human T cells or tumor infiltrating lymphocytes (TILs), which may be transformed to express chimeric antigen receptors (CARs) or T cell receptors (TCRs), and / or mutated by gene editing. In some embodiments, populations of expanded T cells using the media and / or methods provided herein can secrete IL-9, with increased viability, persistence, down-regulation of depletion, mitosis, activation response, early memory T cell phenotypes, or tumor control, and / or with an increased proportion of CD4 + / CD8 + T cells, relative to control populations of T cells.

The present invention relates to the field of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood tissue barrier shielded organs having a large number of populations of post-mitotic neurons, such as organs derived from neural tubes, including the central nervous system and the eye. The disclosed methods and compositions involve topically applying into such organs a combination of an effector component that targets a biological target in a cell, and a saponin component that promotes effective ingestion of the effector component into the cell and / or enhances effective path steering of the effector component within the cell in which the biological target is present. For example, the effector component may be an oligonucleotide therapeutic agent targeting gene products associated with CNS and / or disorders of the eye. Due to the cellular uptake stimulating effect and / or endosomal escape enhancing effect of the saponin component, the neuropharmaceutical and ophthalmic compositions presented herein for topical administration into the CNS and / or eye, respectively, may be formulated with lower concentrations of effector components and / or in smaller volumes, this brings safety benefits to the neurons and the comfort of the patient.

The invention relates to the technical field of cell biology, and discloses a chromosome aberration test method which comprises the following steps: inoculating CHL cells into a plate with the diameter of 100mm, and culturing in a carbon dioxide incubator at 37 DEG C for 24 hours; 4 hours before the cells are harvested, adding a colchicine solution to block the cells in a mitosis metaphase; adding 0.075 mol / L KCL solution for resuspending the cells, and putting the cells into a water bath of about 37 DEG C for hypotonic for 30 minutes to expand the cells; 5 min before the hypotonic treatment is finished, 1 mL of fixing liquid is added for pre-fixing, after uniform mixing, 200 G centrifugation is conducted for 5-7 min, and supernate is discarded; slowly adding 5mL of fresh stationary liquid, uniformly mixing, fixing in a water bath at about 37 DEG C for 30 minutes, reversing uniformly mixed cells every 10 minutes in the process to fully fix, centrifuging at 300G for 10 minutes, discarding supernate, and fixing twice by the same method; adding a set amount of stationary liquid to resuspend the cells, and fixing overnight at 4 DEG C; the chromosome aberration test method provided by the invention solves the technical problem that the chromosome aberration condition in the genetic toxicology test is not easy to observe in the prior art.

Mitosis may be detected using a two-step detection method. This type of detection method may include obtaining a detection output by applying a detection model to a tissue image. Subsequently, for each core in the set of cores identified as undergoing mitotic in the detection output, a deterministic determination is made for that core. Then, for each core in the subset of cores, a classification model may be applied to the core based on a relationship between the confidence of the core and a first threshold. An output may then be provided that identifies each core in the detection output that is identified as experiencing mitotic and whose confidence is above a first threshold as being experiencing mitotic. Further, the output may identify each of the subset of cores that is identified as being subjected to mitosis in the classification results obtained for that core as being subjected to mitosis.

Compositions of Allopregnanolone (Allo), and methods of use thereof for treating and preventing Alzheimer's Disease (AD) or dementia have been developed. In some embodiments, the amount of Allo effective to treat AD or dementia is between about 2 mg and about 10 mg, preferably 4 mg per dose. Methods for identifying subjects for treatment of AD or dementia are also provided. The methods include selecting a subject having one or more Apo E4 gene alleles. Methods of treating a human subject having AD or at risk of AD OR DEMENTIA are provided. The methods include administering a dosage of from 2 mg to 6 mg to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently. The methods stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes.

This invention discloses a method for rice to withstand heat stress. RMI1 Genes and their applications. Among them... RMI1 The nucleotide sequence of the gene is shown in SEQ ID No. 1, and the amino acid sequence of the protein it encodes is shown in SEQ ID No. 2; this invention verifies RMI1 The function of the gene, RMI1 protein is located in the cell nucleus, rmi1-1 In mutants RMI1 The deletion of 33 base pairs in the gene results in the loss of 11 amino acids in the RMI1-1 protein, making... rmi1-1 High temperatures during the seedling stage cause a large number of abnormal chromosomes to adhere and fragment during the late mitotic phase of root tip cells, resulting in stunted plant growth and development. rmi1-1 High temperatures during the reproductive growth period of plants lead to a large number of chromosome fragments and adhesions in the late stage of meiosis I, resulting in sterility; high temperatures also affect the interaction between RMI1-1 protein and topoisomerase TOP3α and helicase RECQ4. rmi1-cr3 Frameshift mutations lead to abnormal embryo and endosperm development; overexpression RMI1 This invention can enhance the heat resistance of rice. RMI1 The analysis of gene function provides genetic resources for the breeding of heat-resistant rice varieties.

The invention provides an umbilical cord matrigel stem cell culture medium as well as a preparation method and application thereof, and belongs to the technical field of stem cells. Comprising the following raw materials: polyethylene glycol, cane sugar, an exosome composition, a cell factor composition, globulin, tween-80 and a PBS buffer solution. The culture medium can promote the growth of cell mitosis and mesoderm cells, the cells are not prone to deformation in in-vitro culture, the cell clone formation rate retention rate after multiple passage is high, the cells can still keep the characteristics of primary cells after being gradually differentiated, and the culture medium has wide application prospects.

The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

The invention relates to a method of preparing a suspension of mitotically suppressed cells, comprising the steps of a) providing cells suspended in a cell culture medium, and b) suppressing the mitotic activity of the cells in the suspension, thereby obtaining mitotically suppressed cells. The step of suppressing the mitotic activity of the cells comprises the step of hypotonic treating the suspension, followed by exposing the cells to at least one freeze-thaw cycle, or vice versa or exposing the cells to two or more freeze-thaw cycles, optionally preceded by a hypotonic treatment of the suspension. In the method of the present invention the hypotonic treatment of the suspension comprises the step of adding liquid, such as water, to the suspension comprising the cells to form a hypotonic cell culture medium. The invention further relates to a method for culturing cells of interest and to the use of a hypotonic cell culture medium.

The invention discloses a drug controlled release system based on optimal drug delivery sequence optimization and a preparation method and application thereof, and belongs to the field of pharmaceutics. The preparation method comprises the following steps: preparing a docetaxel nano preparation, and preparing poloxamer F-127 gel by adopting a cold dissolving method; metformin is dissolved in PBS to prepare a metformin solution, poloxamer F-127 gel, the metformin solution and an aqueous solution of a docetaxel nano preparation are stirred and dispersed uniformly in proportion to a homogeneous sol state, and the drug controlled release system optimized based on the optimal drug delivery sequence is obtained. According to the innovatively designed drug controlled release system MD (at) Gel, based on drug molecular weight and hydrophilic and hydrophobic differences, the metformin released firstly can block tumor cells in a mitosis G2 / M region, and the anti-tumor effect of docetaxel is remarkably improved by improving the immunosuppression microenvironment of tumors. The invention provides an innovative administration strategy and implantable instrument support for sequential chemotherapy of solid tumors.

The application discloses application of an RB1 mutant in a neurodegenerative disease. The application finds through experiments that juvenile fish and adult heterozygotes of a zrb1-KO mutant zebrafish (2 bases are deleted at positions 67 and 68 of the 2nd exon of an rb1 gene) exhibit motor and memory learning dysfunction, exhibit increased post-mitotic neuron apoptosis in the hindbrain, and have the characteristics of a neurodegenerative disease, and therefore, the zrb1-KO mutant zebrafish can be used to construct an animal model of a neurodegenerative disease. In addition, the application also statistically analyzes the mutation frequency and mutation type of RB1 of a neurodegenerative disease patient, and verifies the pathogenicity of R621S and L819V mutations of RB1 in neuron apoptosis through experiments, thereby providing an effective approach for diagnosis or treatment of a neurodegenerative disease.

The application discloses application of a separating enzyme inhibitor in preparation of an antitumor drug, and the separating enzyme inhibitor is toxoflavin and a derivative thereof. The compound can inhibit, at a molecular level, cleavage activity of an important proteinase, namely separating enzyme, on one subunit Scc1 of a mucin; at a cellular level, the toxoflavin derivative Walrycin B can inhibit proliferation of cancer cells such as human cervical cancer (HeLa), liver cancer (HepG2), breast cancer (MCF-7) and prostate cancer (PC3), and can arrest the cell cycle of the cancer cells at a G2 / M phase; and at an allogeneic transplantation tumor animal model, the Walrycin B can significantly inhibit growth of a mouse tumor.

The invention relates to a double-organelle targeted phototherapy fluorescent probe for observing morphological change of a cell nucleus. The structural formula of the double-organelle targeted phototherapy fluorescent probe is shown in the specification. The invention further provides a synthesis method of the probe and application of the probe in organelle targeted imaging, cell mitosis imaging, reactive oxygen evaluation in solutions or cells, tumor cell apoptosis promotion and the like.

The invention relates to a neural tissue unit for use in implantation into the nervous system of a human or non-human mammal, wherein said neural tissue unit contains differentiated post-mitotic neuronal cells in an extracellular matrix, said unit being obtained from a cellular microcompartment comprising a hydrogel capsule surrounding the neural tissue unit, and said hydrogel capsule being at least partially removed before use of the neural tissue unit. The invention also relates to a process for preparing such a neural tissue unit.

The present application relates to the field of aquatic organism breeding technology, and particularly relates to a method for preparing rainbow trout tetraploid fry. The method provided by the present application comprises the following steps: obtaining fertilized eggs by dry fertilization of naturally matured rainbow trout parents, inducing the rainbow trout fertilized eggs to obtain tetraploid rainbow trout after 6.2-6.4 hours, and the duration of the induction is 10-18 minutes; after the tetraploid rainbow trout fry is obtained by induction, the chromosome ploidy of the fish is determined by using techniques such as chromosome karyotype analysis and flow cytometry DNA content determination, and the tetraploid rainbow trout fry is identified and screened for cultivation. The present application adopts a drug induction method, and controls the starting time and duration of the induction to inhibit the first mitosis time of the fertilized eggs, thereby improving the induction rate and survival rate of the tetraploid rainbow trout, and the induction rate of the tetraploid rainbow trout can reach 25-30%, and the survival rate of the fry can reach more than 90%.

The invention relates to the technical field of pharmacy, in particular to a small-molecule inhibitor, a synthesis method and application. The small-molecule inhibitor is a chemical structural formula shown in a formula (I) or a pharmaceutically acceptable salt of the chemical structural formula shown in the formula (I). The small-molecule inhibitor disclosed by the invention has biological activity, can effectively inhibit cell mitosis, and has important significance for preventing abnormal cell proliferation and cancer. # imgabs0 #

Systems and methods for digital pathology and mitosis detection in accordance with embodiments of the invention are illustrated. One embodiment includes a method for performing human-AI digital pathology. The method includes receiving at least one whole slide images (WSIs) of tissues, pre-processing the received WSIs, and generating meningioma grades for the received WSIs. The method further includes providing evidence justifying the generated meningioma grades, receiving updates regarding the provided evidence, and updating the meningioma grades based on the received updates.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

The invention discloses an intestinal cancer mouse model based on Par3L gene knockout and a construction method thereof. After sgRNA is designed to knock out a promoter and a first exon of a Par3L gene of a mouse, the progeny of the obtained gene knockout mouse can spontaneously form intestinal cancer along with the increase of age, and the progeny is accompanied with a tissue infiltration phenotype. The intestinal cancer mouse model constructed by the invention can cause abnormal mitosis of intestinal cells and influence the genome stability, a good model system is provided for further research on the occurrence mechanism of intestinal cancer, and the intestinal cancer mouse model has a wide application prospect.